Skip to main content

Table 1 Model variables: transition probabilities

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

  Sensitivity analysis
Base value Minimum Maximum Distribution
Combination therapy     
 Progression 0.38191794 0.28643845 0.47739742 Binomial
 Death 0.18161864 0.13621398 0.2270233 Binomial
 Complication 0.0846049 0.06345368 0.10575613 Binomial
Monotherapy     
 Progression 0.55459395 0.41594546 0.69324243 Binomial
 Death 0.26230083 0.19672562 0.32787604 Binomial
 Complication 0.1126958 0.08452185 0.14086975 Binomial